JP2022518507A5 - - Google Patents
Info
- Publication number
- JP2022518507A5 JP2022518507A5 JP2021542397A JP2021542397A JP2022518507A5 JP 2022518507 A5 JP2022518507 A5 JP 2022518507A5 JP 2021542397 A JP2021542397 A JP 2021542397A JP 2021542397 A JP2021542397 A JP 2021542397A JP 2022518507 A5 JP2022518507 A5 JP 2022518507A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024102181A JP7823117B2 (ja) | 2019-01-25 | 2024-06-25 | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796953P | 2019-01-25 | 2019-01-25 | |
| US62/796,953 | 2019-01-25 | ||
| PCT/US2020/014998 WO2020154626A1 (en) | 2019-01-25 | 2020-01-24 | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102181A Division JP7823117B2 (ja) | 2019-01-25 | 2024-06-25 | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022518507A JP2022518507A (ja) | 2022-03-15 |
| JPWO2020154626A5 JPWO2020154626A5 (https=) | 2023-11-27 |
| JP2022518507A5 true JP2022518507A5 (https=) | 2023-11-27 |
| JP7511566B2 JP7511566B2 (ja) | 2024-07-05 |
Family
ID=69740563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542397A Active JP7511566B2 (ja) | 2019-01-25 | 2020-01-24 | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
| JP2024102181A Active JP7823117B2 (ja) | 2019-01-25 | 2024-06-25 | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102181A Active JP7823117B2 (ja) | 2019-01-25 | 2024-06-25 | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220235121A1 (https=) |
| EP (1) | EP3914617B1 (https=) |
| JP (2) | JP7511566B2 (https=) |
| KR (2) | KR20210119420A (https=) |
| CN (2) | CN117838856A (https=) |
| AU (3) | AU2020213121A1 (https=) |
| BR (1) | BR112021014472A2 (https=) |
| CA (1) | CA3127797A1 (https=) |
| DK (1) | DK3914617T3 (https=) |
| ES (1) | ES2980453T3 (https=) |
| FI (1) | FI3914617T3 (https=) |
| HU (1) | HUE067202T2 (https=) |
| LT (1) | LT3914617T (https=) |
| MX (1) | MX2021008919A (https=) |
| PL (1) | PL3914617T3 (https=) |
| PT (1) | PT3914617T (https=) |
| SI (1) | SI3914617T1 (https=) |
| WO (1) | WO2020154626A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| SI3658184T1 (sl) | 2017-07-27 | 2024-01-31 | Alexion Pharmaceuticals, Inc., | Formulacije z visoko koncentracijo protiteles proti-C5 |
| CA3080187A1 (en) | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| WO2020006266A1 (en) | 2018-06-28 | 2020-01-02 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| CN112996561A (zh) | 2018-10-30 | 2021-06-18 | 亚力兄制药公司 | 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用 |
| KR20230134533A (ko) * | 2021-01-22 | 2023-09-21 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-c5 항체를 이용한 보체 매개 혈전성 미세혈관병증의치료 방법 |
| EP4333845A1 (en) * | 2021-05-07 | 2024-03-13 | Novartis AG | Iptacopan for the treatment of atypical hemolytic uremic syndrome |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| WO2014099546A1 (en) | 2012-12-19 | 2014-06-26 | Promerus, Llc | Process for the preparation of high purity norbornene alkanols and derivatives thereof |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| EP3402816A1 (en) * | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| SI3658184T1 (sl) * | 2017-07-27 | 2024-01-31 | Alexion Pharmaceuticals, Inc., | Formulacije z visoko koncentracijo protiteles proti-C5 |
| CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| JP7577542B2 (ja) * | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
-
2020
- 2020-01-24 CA CA3127797A patent/CA3127797A1/en active Pending
- 2020-01-24 AU AU2020213121A patent/AU2020213121A1/en not_active Abandoned
- 2020-01-24 DK DK20708762.8T patent/DK3914617T3/da active
- 2020-01-24 LT LTEPPCT/US2020/014998T patent/LT3914617T/lt unknown
- 2020-01-24 KR KR1020217024820A patent/KR20210119420A/ko not_active Ceased
- 2020-01-24 KR KR1020257001928A patent/KR20250016490A/ko active Pending
- 2020-01-24 FI FIEP20708762.8T patent/FI3914617T3/fi active
- 2020-01-24 JP JP2021542397A patent/JP7511566B2/ja active Active
- 2020-01-24 PL PL20708762.8T patent/PL3914617T3/pl unknown
- 2020-01-24 PT PT207087628T patent/PT3914617T/pt unknown
- 2020-01-24 WO PCT/US2020/014998 patent/WO2020154626A1/en not_active Ceased
- 2020-01-24 US US17/424,794 patent/US20220235121A1/en not_active Abandoned
- 2020-01-24 EP EP20708762.8A patent/EP3914617B1/en active Active
- 2020-01-24 CN CN202410035211.2A patent/CN117838856A/zh active Pending
- 2020-01-24 HU HUE20708762A patent/HUE067202T2/hu unknown
- 2020-01-24 CN CN202080016936.7A patent/CN113614105A/zh active Pending
- 2020-01-24 ES ES20708762T patent/ES2980453T3/es active Active
- 2020-01-24 BR BR112021014472-2A patent/BR112021014472A2/pt unknown
- 2020-01-24 MX MX2021008919A patent/MX2021008919A/es unknown
- 2020-01-24 SI SI202030425T patent/SI3914617T1/sl unknown
-
2024
- 2024-06-25 JP JP2024102181A patent/JP7823117B2/ja active Active
- 2024-11-22 AU AU2024266818A patent/AU2024266818B2/en active Active
-
2026
- 2026-02-04 AU AU2026200805A patent/AU2026200805A1/en active Pending